BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

...Mike Grey as chairman. The financing, led by Lux Capital...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...and Intel Capital. Also participating were existing backers New Enterprise Associates, 8VC, Amgen Ventures and Lux Capital...
BioCentury | Aug 20, 2020
Finance

Science 37, Castor raise funds as decentralized trials gain traction

...Pandemic?”).Science 37 Inc. raised $40 million in a series D1 round led by existing investors Lux Capital...
BioCentury | Apr 18, 2020
Finance

April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern

...the rare-disease focused real-world evidence company to expand into 20 additional indications. Existing seed investors Lux Capital...
BioCentury | Mar 25, 2020
Finance

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

...disease. All of Kallyope Inc.’s series B investors backed the new round: The Column Group, Lux Capital...
BioCentury | Jul 15, 2019
Financial News

AI play Recursion raises $121M to expand into new drug discovery

...Minnesota and Texas Tech University System. Undisclosed angel investors and all existing institutional investors, including Lux Capital...
BioCentury | Jan 3, 2019
Emerging Company Profile

Auransa’s AI-predicted pipeline

...Cell Theranostics Inc. Number of employees: 25 Funds raised: $24 Million Investors: Data Collective (DCVC), Lux Capital...
BioCentury | Dec 7, 2018
Financial News

Gates leads Kallyope's $21M B round expansion

...NASH), and neurological diseases including mood disorders and Parkinson’s disease (see "Data-Driven" ). Existing investors Lux Capital...
BioCentury | Dec 5, 2018
Financial News

Gates leads Kallyope's $21M B round expansion

...NASH), and neurological diseases including mood disorders and Parkinson’s disease (see "Data-Driven" ). Existing investors Lux Capital...
BioCentury | Aug 31, 2018
Financial News

Real-world data play RDMD raises $3M seed round

...Calif.) raised $3 million on Aug. 20 in a seed round led by new investor Lux Capital...
Items per page:
1 - 10 of 79
BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

...Mike Grey as chairman. The financing, led by Lux Capital...
BioCentury | Jan 6, 2021
Finance

Senti banks $105M series B as Bayer continues to show enthusiasm for gene and cell therapy biotechs

...and Intel Capital. Also participating were existing backers New Enterprise Associates, 8VC, Amgen Ventures and Lux Capital...
BioCentury | Aug 20, 2020
Finance

Science 37, Castor raise funds as decentralized trials gain traction

...Pandemic?”).Science 37 Inc. raised $40 million in a series D1 round led by existing investors Lux Capital...
BioCentury | Apr 18, 2020
Finance

April 17 Quick Takes: Mabworks’ $160M series C; plus RDMD, PIC, SIRS, Atomo and Lantern

...the rare-disease focused real-world evidence company to expand into 20 additional indications. Existing seed investors Lux Capital...
BioCentury | Mar 25, 2020
Finance

‘Diversified’ gut-brain axis company Kallyope heading to clinic with $112M series C

...disease. All of Kallyope Inc.’s series B investors backed the new round: The Column Group, Lux Capital...
BioCentury | Jul 15, 2019
Financial News

AI play Recursion raises $121M to expand into new drug discovery

...Minnesota and Texas Tech University System. Undisclosed angel investors and all existing institutional investors, including Lux Capital...
BioCentury | Jan 3, 2019
Emerging Company Profile

Auransa’s AI-predicted pipeline

...Cell Theranostics Inc. Number of employees: 25 Funds raised: $24 Million Investors: Data Collective (DCVC), Lux Capital...
BioCentury | Dec 7, 2018
Financial News

Gates leads Kallyope's $21M B round expansion

...NASH), and neurological diseases including mood disorders and Parkinson’s disease (see "Data-Driven" ). Existing investors Lux Capital...
BioCentury | Dec 5, 2018
Financial News

Gates leads Kallyope's $21M B round expansion

...NASH), and neurological diseases including mood disorders and Parkinson’s disease (see "Data-Driven" ). Existing investors Lux Capital...
BioCentury | Aug 31, 2018
Financial News

Real-world data play RDMD raises $3M seed round

...Calif.) raised $3 million on Aug. 20 in a seed round led by new investor Lux Capital...
Items per page:
1 - 10 of 79